MedPath

Tetryzoline

Generic Name
Tetryzoline
Brand Names
Colirio Ocusan, Visine
Drug Type
Small Molecule
Chemical Formula
C13H16N2
CAS Number
84-22-0
Unique Ingredient Identifier
S9U025Y077
Background

Tetryzoline, also known as tetrahydrozoline, is a derivative of imidazoline with central and peripheral alpha (α)-adrenergic properties. Available since the 1950s, tetryzoline is a selective α-receptor agonist that is used as an ocular and nasal decongestant. Tetryzoline is found in a wide array of over-the-counter eye drops, including the most common brand, Visine. Tetryzoline is also found in combination products with other lubricants and anti-irritants, such as povidone, polyethylene glycol 400, dextran, and zinc sulfate. It is also used in combination with other drug classes, such as antihistamines, corticosteroids, and glucocorticoids in other countries. Tetryzoline is also found in nasal spray under the trade name Tyzine, which is used for decongestion of nasal and nasopharyngeal mucosa.

As it causes profound sedation in children and adults, tetryzoline is increasingly becoming scrutinized for possible drug overdose and toxicity from accidental ingestion. It has also been misused for non-therapeutic purposes as a causative drug for several cases of drug-facilitated sexual assault.

Indication

用于过敏性结膜炎、急性或慢性结膜炎,也可用于花粉症所引起的充血性结膜炎、灼热及痒感、眼疲倦。亦可用于由于配戴眼镜、阅读、看电视、暗室工作引起的视疲劳。

Associated Conditions
Active, Symptomatic Blepharitis, Allergic Conjunctivitis (AC), Blepharitis allergic, Blepharoconjunctivitis, Chalazion, Conjunctivitis, Conjunctivitis, Vernal, Dacryocystitis, Dry Eyes, Episcleritis, Eye allergy, Eye pruritus, Eye redness, Eyelid folliculitis, Keratitis, Keratoconjunctivitis, Nasal Congestion, Nasal oedema, Ocular Inflammation, Ocular Irritation, Pterygium, Red eye, Rhinopharyngitis, Scleritis, Sinusitis, Acute Rhinitis, Bacterial blepharitis, Conjunctival hyperemia, Eye discomfort, Sensation of burning in the eyes, Subacute Rhinitis, Swelling of the eyes
Associated Therapies
Ocular vasoconstriction therapy

Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

Phase 2
Recruiting
Conditions
Fuchs Endothelial Corneal Dystrophy
Interventions
Drug: N-acetyl cysteine (NAC) 10% solution
Drug: N-acetyl cysteine (NAC) 20% solution
First Posted Date
2020-06-19
Last Posted Date
2025-05-21
Lead Sponsor
Massachusetts Eye and Ear Infirmary
Target Recruit Count
45
Registration Number
NCT04440280
Locations
🇺🇸

Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States

A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE)

Phase 4
Completed
Conditions
Contact Lens Dry Eye
Interventions
First Posted Date
2010-04-16
Last Posted Date
2011-09-26
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
50
Registration Number
NCT01105624
Locations
🇺🇸

The Ohio State University, College of Optometry, Columbus, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath